Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Myxoid Leiomyosarcoma of the Uterus in a Patient Receiving Tamoxifen Therapy: A Case Report

Botsis, Dimitris M.D., Ph.D.; Koliopoulos, Carolina M.D., Ph.D.; Kondi-Pafitis, Agathi M.D., Ph.D.; Creatsas, George M.D., Ph.D., F.A.C.S.

International Journal of Gynecological Pathology: April 2006 - Volume 25 - Issue 2 - p 173-175
doi: 10.1097/01.pgp.0000185407.93308.ce
Case Reports

Summary: In this paper, we present a case of myxoid leiomyosarcoma development in a patient receiving tamoxifen for 3 years because of breast cancer. The myxoid leiomyosarcoma should be included in the differential diagnosis of any uterine tumor with a predominantly myxomatous composition. A review of the literature indicates that tamoxifen may increase not only the risk for endometrial cancer but also for uterine sarcoma, suggesting vigilance for uterine cancer in women who are being treated with this drug.

From the Second Department of Obstetrics and Gynecology (D.B., C.K., G.C.), University of Athens, Areteion University Hospital, Athens, Greece; and Pathology Laboratory (A.K.-P.), Areteion University Hospital, Athens, Greece

Address correspondence and reprint requests to Carolina Koliopoulos, 35 Vassilisis Sophias Avenue, 10675 Athens, Greece. E-mail:

©2006International Society of Gynecological Pathologists